Researcher Spotlight: Robert Albero Gallego, PhD COLUMBIA UNIVERSITY Angioimmunoblastic T-cell lymphomas (AITLs) are aggressive forms of blood cancer and are often resistant to conventional chemotherapy. Certain mutations have been to be very common in AITLs, including mutations in the TET2…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Haopeng Yang, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Super-enhancers are regions of the genome responsible for regulating expression of an unusually high number of genes. For his Lymphoma Research Foundation-funded project, Dr. Yang is characterizing the…
Researcher Spotlight: Min Xia, PhD WEILL CORNELL MEDICINE Among the different subtypes of diffuse large B-cell lymphoma (DLBCL), ABC-DLBCL represents one of the most aggressive forms with low response rates to standard chemotherapeutic approaches. Improved treatment approaches in this space…
Researcher Spotlight: Christoph Weigel, PhD THE OHIO STATE UNIVERSITY Epstein-Barr Virus (EBV) is a ubiquitous virus that infects many people across the globe without any serious or immediate symptoms. In certain circumstances, however, such as older age or after organ…
Researcher Spotlight: David Russler-Germain, MD, PhD WASHINGTON UNIVERSITY IN ST. LOUIS Follicular lymphoma (FL) is typically a slow-growing disease with high response rates to initial therapy, but disease outcomes vary considerably from patient to patient. Dr. Russler-Germain, therefore, is researching…
Researcher Spotlight: Caitlin Gribbin, MD NEW YORK-PRESBYTERIAN/WEILL CORNELL The Kellie and Jeff Fellinge Scholar The follicular lymphoma (FL) tumor microenvironment is made up of a wide variety of non-lymphoma cells that contribute to the growth and progression of tumor cells.…
Researcher Spotlight: Danielle Wallace, MD UNIVERSITY OF ROCHESTER Mindy Camp Fedida Memorial Scholar Older patients with diffuse large B-cell lymphoma (DLBCL) are often treated with lower doses of chemotherapy, which may contribute to an incomplete cure of the disease. Residual…
Researcher Spotlight: Lauren Shea, MD UNIVERSITY OF ALABAMA Kanti R. Rai, MD Clinical Scholar Better therapies are needed for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and Dr. Shea’s research aims to identify a novel, improved treatment approach…
Researcher Spotlight: Christina Poh, MD UNIVERSITY OF WASHINGTON/FRED HUTCHINSON CANCER CENTER Stephanie A. Gregory, MD Distinguished Scholar Survival outcomes with peripheral T-cell lymphoma (PTCL) are poor, with many patients relapsing after their first line of treatment and only about 1…